摘要
目的探讨赛沃替尼治疗间质上皮细胞转化因子(MET)突变非小细胞肺癌(NSCLC)的临床疗效。方法回顾性分析2021年7月—2023年7月本院收治的82例MET突变NSCLC患者作为研究对象,根据不同治疗方法分为观察组和对照组两组,每组各41例。对照组予以奥希替尼治疗,观察组在常规化疗基础上加以赛沃替尼治疗。比较两组全身疗效、治疗前后血清肿瘤标志物水平、不良反应发生情况及治疗前后生活质量水平变化。结果治疗后观察组14例CR、16例PR、7例SD、4例PD,对照组例7例CR、14例PR、12例SD、8例PD,观察组全身疗效总有效率显著高于对照组(73.17%vs 51.22%)(P<0.05)。与治疗前对比,治疗后两组血清肿瘤标志物CEA、CA125、CYFRA21-1水平均降低(P<0.05),且观察组降低幅度更显著(P<0.05)。观察组与对照组不良反应中皮疹(29.27%vs 26.83%)、肝功能损害(60.98%vs 65.85%)、胃肠道反应(24.39%vs 26.83%)、骨髓抑制(17.07%vs 14.63%)、神经毒性(29.27%vs 31.71%)、外周水肿(41.46%vs 31.71%)发生率对比,差异均无统计学意义(P>0.05)。与治疗前对比,治疗后两组社会/家庭状况、功能状况、情感状况、生理状况得分均升高(P<0.05),且观察组升高幅度更明显(P<0.05)。结论赛沃替尼治疗MET突变NSCLC患者能有效提升临床治疗效果及生活质量,改善血清肿瘤标志物水平,且不会增加严重不良反应,值得推广。
Objective To investigate the clinical efficacy of Savolitinib in the treatment of mesenchymal epithelial transforming factor(MET)mutated non-small cell lung cancer(NSCLC).Methods A total of 82 patients with MET mutated NSCLC who were admitted to the hospital from July 2021 to July 2023 and met the inclusion and exclusion criteria were selected and enrolled as study subjects.They were divided into the observation group(41 cases)and the control group(41 cases)according to different treatment methods.The control group was treated with osimertinib,and the observation group was treated with Savolitinib on the basis of conventional chemotherapy.Systemic efficacy,serum tumor marker level before and after treatment,occurrence of adverse reactions and quality of life before and after treatment were compared between the two groups.Results After treatment,there were 14 cases of CR,16 cases of PR,7 cases of SD and 4 cases of PD in the observation group,and 7 cases of Cr,14 cases of PR,12 cases of SD and 8 cases of PD in the control group.The total effective rate of the observation group was significantly higher than that of the control group(73.17%vs 51.22%)(P<0.05).Compared with before treatment,the levels of serum tumor markers CEA,CA125 and CYFRA21-1 in the two groups were decreased after treatment(P<0.05),and the reduction was more significant in the observation group(P<0.05).There were no significant difference in the adverse reactions including rash(29.27%vs 26.83%),liver function impairment(60.98%vs 65.85%),gastrointestinal reaction(24.39%vs 26.83%),bone marrow suppression(17.07%vs 14.63%),neurotoxicity(29.27%vs 31.71%)and peripheral water swelling(41.46%vs 31.71%)between the observation group and the control group(P>0.05).Compared with before treatment,the scores of social/family status,functional status,emotional status and physiological status in the 2 groups were all increased after treatment(P<0.05),and the increases in the observation group were more significant(P<0.05).Conclusions The treatment of patients with MET mutated NSCLC with Savolitinib can effectively improve the clinical therapeutic effect and quality of life,improve the level of serum tumor markers,and does not increase serious adverse reactions,which is worthy of promotion.
作者
张茹
孙凡
王进隆
刘璐璐
屈中玉
Zhang Ru;Sun Fan;Wang Jinlong;Liu Lulu;Qu Zhongyu(Department of Oncology,Nanyang Central Hospital,Nanyang,Henan 473000,China.)
出处
《齐齐哈尔医学院学报》
2024年第6期540-543,共4页
Journal of Qiqihar Medical University
关键词
赛沃替尼
间质上皮细胞转化因子
基因突变
非小细胞肺癌
Savolitinib
Mesenchymal epithelial cell transformation factor
Gene mutation
Non-small cell lung cancer
作者简介
通信作者:屈中玉,Email:zhongmin_1981@163.com。
